SPOTLIGHT -
With no clear-cut set of signs and symptoms to advertise its presence, experts suggest diagnosis may require MRI, transvaginal U/S, and/or needle biopsy. Among your treatment options: hysterectomy, GnRH agonists, and the levonorgestrel IUD.
Contemporary OB/GYN week in review: Pregnancy prevention, postpartum depression, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Read More
How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care
Listen
ZY5301 tablet effective for chronic pelvic pain
These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.
The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels
cUTI Roundtable: The latest therapeutic developments
The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
FDA approves femlyv as the first orally disintegrating tablet for pregnancy prevention
Femlyv, containing norethindrone acetate and ethinyl estradiol, offers a new oral contraceptive option for individuals with swallowing difficulties, expanding access and convenience.